BCRT Genome Engineering Club
|BCRT Genome Engineering Club||03.06.2019 16:00 - 17:00||IGS 0.0043|
Kevin Holden (Head of Synthetic Biology at Synthego Corporation)
Novel Automation Platforms for Generating Synthetic sgRNA and CRISPR-Engineered Cells at Scale
Synthego has developed a novel synthesis architecture for the production of chemically modified sgRNAs that are ideal for therapeutic applications of CRISPR ranging from research in primary cell types to clinical gene therapies. This synthesis architecture allows for the production of hundreds of thousands of unique sgRNAs and also for the production of large quantities of clinically relevant sgRNAs in a GMP setting. In addition, the consistent nature of chemically synthesized sgRNAs allows for their application to computational biology for building bioinformatic tools for prediction and analysis of CRISPR editing. We will describe a set of novel automation platforms that combines these advantages into generating an automated workflow for generating CRISPR-engineered cells at scale.
|Research Highlights May 2019|